|
Main /
AZMain.AZ History2021 年 08 月 29 日，M 上午
被 -
更新第 7 行從：
* [[T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial|https://www.nature.com/articles/s41591-020-01194-5]] 為
* [[https://www.nature.com/articles/s41591-020-01194-5|T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial]] 2021 年 08 月 29 日，M 上午
被 -
增加 7-8 行
* [[T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial|https://www.nature.com/articles/s41591-020-01194-5]] 2021 年 08 月 29 日，M 上午
被 -
更新 6-7 行從：
-> (有AZ不同劑別/不同週期接種第二劑的反應) 為
-> (有AZ不同劑別/不同週期接種第二劑的反應) * [[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1007573/S1332_How_long_will_vaccines_continue_to_protect_against_COVID-19.pdf|How long will vaccines continue to protect against COVID? ]] 2021 年 08 月 28 日，M 下午
被 -
更新 3-6 行從：
* [[https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/pfizer-astrazeneca-vaccine-antibody-levels-lancet-study-1833183-2021-07-27|Pfizer, AstraZeneca vaccine antibodies may reduce by 50% after 2-3 months: Lancet study]] 為
* [[https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/pfizer-astrazeneca-vaccine-antibody-levels-lancet-study-1833183-2021-07-27|Pfizer, AstraZeneca vaccine antibodies may reduce by 50% after 2-3 months: Lancet study]] * [[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1012661/uk-spc-covid-19-vaccine-astrazeneca-reg174-gbs-clean.pdf|COVID-19 Vaccine AstraZeneca UK - GOV.UK]] -> (有AZ不同劑別/不同週期接種第二劑的反應) 2021 年 08 月 28 日，M 下午
被 -
更新 1-3 行從：
* [[https://www.nature.com/articles/s41591-020-01194-5|T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial]] 為
* [[https://www.nature.com/articles/s41591-020-01194-5|T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial]] * [[https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/pfizer-astrazeneca-vaccine-antibody-levels-lancet-study-1833183-2021-07-27|Pfizer, AstraZeneca vaccine antibodies may reduce by 50% after 2-3 months: Lancet study]] 2021 年 08 月 28 日，M 下午
被 -
增加第 1 行
* [[https://www.nature.com/articles/s41591-020-01194-5|T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial]] |